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Mutations in CTC1, Encoding the CTS Telomere
Maintenance Complex Component 1, Cause Cerebroretinal
Microangiopathy with Calcifications and Cysts
Anne Polvi,1,2,3 Tarja Linnankivi,4 Tero Kivela¨,5 Riitta Herva,6 James P. Keating,7 Outi Ma¨kitie,1,8
Davide Pareyson,9 Leena Vainionpa¨a¨,10 Jenni Lahtinen,11 Iiris Hovatta,11,12 Helena Pihko,4
and Anna-Elina Lehesjoki1,2,3,*
Cerebroretinal microangiopathy with calcifications and cysts (CRMCC) is a rare multisystem disorder characterized by extensive intra-
cranial calcifications and cysts, leukoencephalopathy, and retinal vascular abnormalities. Additional features include poor growth, skel-
etal and hematological abnormalities, and recurrent gastrointestinal bleedings. Autosomal-recessive inheritance has been postulated.
The pathogenesis of CRMCC is unknown, but its phenotype has key similarities with Revesz syndrome, which is caused by mutations
in TINF2, a gene encoding a member of the telomere protecting shelterin complex. After a whole-exome sequencing approach in four
unrelated individuals with CRMCC, we observed four recessively inherited compound heterozygous mutations in CTC1, which encodes
the CTS telomere maintenance complex component 1. Sanger sequencing revealed seven more compound heterozygous mutations in
eight more unrelated affected individuals. Two individuals who displayed late-onset cerebral findings, a normal fundus appearance, and
no systemic findings did not have CTC1mutations, implying that systemic findings are an important indication for CTC1 sequencing.
Of the 11 mutations identified, four were missense, one was nonsense, two resulted in in-frame amino acid deletions, and four were
short frameshift-creating deletions. All but two affected individuals were compound heterozygous for a missense mutation and a frame-
shift or nonsensemutation. No individuals with two frameshift or nonsensemutations were identified, which implies that severe distur-
bance of CTC1 function from both alleles might not be compatible with survival. Our preliminary functional experiments did not show
evidence of severely affected telomere integrity in the affected individuals. Therefore, determining the underlying pathomechanisms
associated with deficient CTC1 function will require further studies.Cerebroretinal microangiopathy with calcifications and
cysts (CRMCC [MIM 612199]) is a rare multisystem
disorder. Its key characteristics include extensive and
progressive intracranial calcifications and leukoence-
phalopathy, and many affected individuals also develop
intracranial cysts (Figures 1A–1F).1 Typically, the cerebral
findings are accompanied by retinal vascular abnormali-
ties, which include both retinal telangiectasias—leading
to bleedings and exudative retinopathy—and angioma-
like excrescences of retinal vessels associated with bleed-
ings and vitreoretinal traction (Figures 1G and 1H).1,2
The retina that is peripheral to these abnormalities is avas-
cular. Abnormal small vessels with thickened walls and
angiomatous proliferations have also been reported in
brain areas that show calcifications.1 Individuals with
CRMCC have previously been described as having one of
two disorders: Coats plus3 or leukoencephalopathy with
calcifications and cysts (LCC).4 However, reports in which
several individuals were found to have characteristics of
both Coats plus and LCC led us to postulate that these1Folkha¨lsan Institute of Genetics, Helsinki 00290, Finland; 2Molecular Medici
Genetics, Haartman Institute, University of Helsinki, Helsinki 00290, Finlan
4Department of Pediatric Neurology, Children’s Castle, Helsinki University C
Helsinki University Central Hospital, Helsinki 00290, Finland; 6Department o
of Pediatrics, Washington University School of Medicine, St. Louis Children’s
of Helsinki and Helsinki University Central Hospital, Helsinki 00290, Finl
Department of Clinical Neurosciences, Fondazione Instituto di Ricovero e Cur
10Department of Pediatrics, Oulu University Hospital, Oulu 90029, Finland; 11M
ment of Medical Genetics, Haartman Institute, University of Helsinki, Helsin
Services, National Institute for Health and Welfare, Helsinki 00271, Finland
*Correspondence: anna-elina.lehesjoki@helsinki.fi
DOI 10.1016/j.ajhg.2012.02.002. 2012 by The American Society of Human
540 The American Journal of Human Genetics 90, 540–549, March 9two entities are in fact manifestations of the same disorder,
CRMCC.1,5
Most CRMCC-affected individuals present in infancy
or early childhood with poor growth and neurological
symptoms, which include spasticity, dystonia, ataxia,
seizures, and obstructive hydrocephalus and/or impaired
vision. The neurological symptoms are slowly progressive
and, in most individuals, are associated with some degree
of cognitive decline.1,2 Affected children typically show
compromised prenatal and postnatal growth. Skeletal
abnormalities include generalized osteopenia or early-
onset low-turnover osteoporosis, fragility fractures with
delayed healing, and metaphyseal abnormalities
(Figure 1I).3,6 Recurrent gastrointestinal hemorrhage due
to telangiectatic or angiodysplastic changes is a life-threat-
ening complication that occurs in up to 40% of individuals
with CRMCC.1,2 Additional findings in some individuals
are portal hypertension, liver failure, and unexplained
anemia and thrombopenia with varying degrees of
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Figure 1. Key Clinical Findings in CRMCC
(A) A T2-weighted magnetic resonance image
(MRI) of a CRMCC-affected individual (age 11
years) shows heterogeneous lesions in both
thalami (black arrows), hyperintensity in the
posterior parts of the internal capsules (white
arrow) and in the right putamen, and a cyst in
the midline (arrowhead).
(B) A T2*-weighted image reveals large calcifica-
tions in thalami (arrow) and in the parieto-occip-
ital regions.
(C) A T2-weighted image of another individual
(age 16 years) with CRMCC shows hyperintense
lesions in the brain stem (arrow).
(D and E) Flair images of a 3-year-old individual
reveal widespread white-matter hyperintensity
in the parieto-occipital regions (arrowheads) as
well as asymmetric thalamic involvement (black
arrow). A stripe-like hypodensity in the subcor-
tical white matter is seen (white arrow) and most
likely represents calcification. Note amidline cyst.
(F) A brain computed tomography (CT) image of
a 3-year-old individual shows dense calcifications
in the subcortical white matter (arrowheads) and
in the brainstem (arrow).
(G and H) Wide-angle fundus photographs of a
15-month-old individual’s eyes show a preretinal
hemorrhage (arrow) associatedwith telangiectatic
retinal vessels (arrowheads), which border avas-
cular peripheral retina in the right eye (G), and
an exudative retinal detachmentwith yellow lipid
exudates in the left eye (H).
(I) Radiographs of the lower limbs of a 14-year-old
individual show osteopenia and abnormal bone
structure (especially in the metaphyseal areas),
bilateral fragility fractures in the proximal tibiae
(arrows), and genua valga.graying, or sparse hair or skin-pigmentation abnormalities
have been reported.2,7,8
CRMCC most often occurs sporadically, but several
families with healthy parents and two or more affected
children of both sexes have been reported,1,2,7,8 suggesting
autosomal-recessive inheritance. Previously, no genes or
variants associated with CRMCC have been reported.
The pathogenesis of this pleiotropic disease remains
unknown, although obliterative microangiopathy has
been suggested as a possible primary underlying patholog-
ical abnormality.1
We employed a whole-exome sequencing strategy in
four apparently unrelated Finnish individuals with
CRMCC. We then Sanger sequenced 11 additional affected
members, three of whomwere non-Finnish, from ten fami-
lies. In addition to the tabulated key features (Table 1),
a detailed clinical description of 10 of the 15 subjects can
be found in three previous papers.1,2,9 The study was
approved by an institutional review board at the Helsinki
University Central Hospital, and written informed consent
was obtained from all study subjects or their legal guard-
ians before peripheral blood was drawn for DNA extrac-
tion.
Whole-exome sequencing was performed in two pairs
of affected individuals with the most similar phenotypes
(F1:II-1 and F6:II-3 had retinal telangiectasias, retinal angi-The Ameomas, and cerebral cysts; F2:II-1 and F5:II-1 had retinal
telangiectasias in the absence of retinal angiomas). Exonic
sequences were enriched from three micrograms of
genomic DNA with NimbleGen SeqCap EZ Human Exome
Library v2.0 (Roche, NimbleGen, USA). Captured DNAwas
amplified with 12 cycles of PCR. We then used Illumina’s
Genome Analyzer IIx platform with a 6 bp index read to
perform massive parallel sequencing of two paired-end
100 bp reads according to the manufacturer’s protocols.
We aligned the two 100 bp paired-end sequence reads to
the hg19 reference genome by using the Burrows-Wheeler
Alignment tool.10 The Pileup utility from the SAMTOOLS
package11 was used for variant calling. Exome sequencing
and variant calling were performed at the Institute for
Molecular Medicine Finland (FIMM) Technology Centre
at the University of Helsinki (for a detailed description of
the procedure, see Sulonen et al., 201112). Variant calling
resulted in more than 80,000 single-nucleotide variants
(SNVs) and 12,000 small insertion-deletion (indel) variants
in each individual (Table S1, available online). Of the
called SNVs, fewer than 6,000 in each individual were
not present in the dbSNP database (build 135). For
whole-exome data analysis, we assumed autosomal-
recessive inheritance and the presence of one or more
deleterious variants in the same gene in all four af-
fected individuals. We considered missense, nonsense,rican Journal of Human Genetics 90, 540–549, March 9, 2012 541
Table 1. Summary of Clinical Features and Mutation Status in 15 CRMCC-Affected Individuals
F1:II-1 F2:II-1 F3:II-1 F4:II-2a F5:II-1 F6:II-3 F7:II-3a F8:II-1 F9:II-2 F10:II-1 F10:II-2 F11:II-1 F12:II-1 F13:II-3 F14: II-1
Patient 21 Patient 11 Patient 16 Patient 51  Patient 41  Patient 121  Patient 81 Patient 61   Patient 131 Patient 19
CTC1 mutation Val665Gly
Pro994fs*
Val665Gly
Pro994fs*
Val665Gly
Pro994fs*
Val665Gly
Pro994fs*
Val665Gly
Leu1142His
Val665Gly
Arg1195*
Val665Gly
Leu1007fs*
Ala227Val
Pro994fs*
Ala227Val
Pro994fs*
Ala227Val
Ser353fs*
Ala227Val
Ser353fs*
Lys242fs*
Arg975Gly
Cys985 del
p.Leu1196_
Arg1202 del
 
Gender F F F F F F M M M F M M M M F
Age at onset 0.5 years 0.9 years 1.5 years 0.5 years 0.6 years 0.5 years at birth 14 years 0.1 years 1.0 years 5.0 years at birth 0.9 years 14 years 27 years
Brain calcifications þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Leukoencephalopathy þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Intracranial cysts þ þ þ   þ þ     þ þ þ þ
Retinal abnormality T, AG,
C, R
T, C, R T, R T, Rb T, C, R T, AG,
C, R
þb  þb T, C, Rb Tb þb þb  
IUGR þ þ þ þ þ þ þ þ þ þ þ þ þ NA 
Osteopenia or
fractures
O O O, F O, F NA O NA O, F NA O O O, F  NA 
GI bleeding þ  þ þ   þ   þ þ þ   
Liver involvement   þ þ       þ þ   
Hematologic findings   AN, TP,
mild LP
AN, TP,
mild LP
     AN,
mild TP
AN, TP,
LP
AN, TP,
mild LP
  
Sparse hair þ þ   þ  þ   þ þ þ   
Mucocutaneous
features
              þc
Cardiac abnormality  ASD CAF  MVSD          
Cleft lip   þ       þ     
Neurologic
symptoms
S, A, D,
SZ, HC,
CD
S, D, CD mild CD S, A, D,
CD
 S, A,
SZ, CD
S, HC,
DD
SZ,
mild CD
DD, HC S, D,
SZ, CD
S, SZ, CD S, SZ S, A S, A, SZ,
CN,CD
S, CN,
mild CD
Current status (age) dead
(6 years
old)
alive
(11 years
old)
dead
(18 years
old)
dead
(13 years
old)
alive
(4 years
old)
alive
(15 years
old)
dead
(1.9 years
old)
alive
(22 years
old)
dead
(1.5 years
old)
dead
(22 years
old)
dead
(16 years
old)
dead
(17 years
old)
alive
(3.8 years
old)
dead
(43 years
old)
alive
(33 years
old)
The following abbreviations are used: F, female; M, male; T, telangiectasia; AG, angiomas; C, Coats reaction; R, retinal detachment; IUGR, intrauterine growth retardation; O, osteopenia; F, fractures; NA, data not available; GI,
gastrointestinal; AN, anemia; TP, thrombopenia; LP, leukopenia; ASD, arterial septal defect; CAF, coronary artery fistulas; MVSD, multiple ventricular septal defects; S, spasticity; A, ataxia; D, dystonia; SZ, seizures; HC, acute
hydrocephalus; CD, cognitive decline; DD, developmental delay; and CN, cranial nerve involvement.
aThe genotypes are inferred from parental genotypes.
bAll clinical information for retinal abnormality was not available; additional findings are possible.
cTwo cafe´ au lait spots.
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Figure 2. Schematic Structure of CTC1 and the Encoded Protein with Relative Positions of the Mutations
The exons in CTC1 are shown to scale as numbered boxes. The untranslated regions are depicted in gray. The introns are shown as lines
and are not to scale. In CTC1, the predicted OB folds are shown as gray boxes. The N-terminal 700 aa region was previously shown to be
involved in DNA binding, which is possibly mediated by the two OB domains, and the following C-terminal region in STN1 binding.14frameshift, and essential splice-site variants as deleterious.
We found that no genes with homozygous mutations ful-
filled our criteria. However, three genes with compound
heterozygous mutations and one gene with a combination
of homozygous and compound heterozygous mutations in
all four individuals were identified (Table S2).
CTC1 (MIM 613129), which encodes the CTS telomere
maintenance complex component 1, was considered as
the primary candidate on the basis of its putative func-
tion and the absence of the identified variants in exomes
of Finnish individuals sequenced at the FIMM Technology
Centre (H. Almusa, personal communication). The
main transcript of CTC1 is composed of 23 exons, and it
encodes a 1,217 aa polypeptide (Figure 2; RefSeq accession
numbers NM_025099.5 and NP_079375.3). All four indi-
viduals (Figure 3) were heterozygous for a c.1994T>G
(p.Val665Gly) missense substitution, two (F1:II-1 and
F2:II-1) were heterozygous for a c.2831delC (p.Pro944-
Leufs*7) mutation causing a frameshift and a premature
stop codon, one (F5:II-1) was heterozygous for a 2 bp indel
(c.3425_3426delTCinsAT) causing a missense substitution
(p.Leu1142His), and one (F6:II-3) was heterozygous for
a c.3583C>T (p.Arg1195*) nonsense mutation (Figures 2
and 3). Conventional Sanger sequencing confirmed the
identified mutations (Figure S1). Genotyping of available
familymembers (Figure 3) confirmed that their segregation
was consistent with autosomal-recessive inheritance.
Next, we used classical Sanger sequencing to sequence
the coding region of CTC1 in the remaining DNA samples
of our entire CRMCC cohort containing nine affected indi-
viduals (in eight families). In addition, only parent DNA
was available for two CRMCC-affected individuals, F4:II-2The Ameand F7:II-3, and we sequenced it to infer the genotypes
of these individuals (Figure 3). The CTC1 mutations iden-
tified were also sequenced in healthy family members.
The primer sequences are given in Table S3, and the PCR
conditions are available from the authors by request. Two
compound heterozygous mutations were identified or in-
ferred innine affected individuals in eight families (Figure 3
and Figure S1), but nomutations were identified in F13:II-3
and F14:II-3. Five individuals carried either just one or
both of the c.1994T>G (p.Val665Gly) and c.2831delC
(p.Pro944Leufs*7) mutations identified in whole-exome
sequencing. In addition, seven more mutations were iden-
tified: two nucleotide substitutions leading to a missense
alteration, three deletions creating a frameshift, and two
in-frame deletions leading to the removal of a cysteine
residue and to a 7 aa deletion (Figure 3 and Figure S1).
The 11 identified mutations occurred in 8 of 23 exons in
CTC1 (Table 2 and Figure 2).
The 11 mutations were absent from both the Exome
Variant Server of the National Heart, Lung, and Blood Insti-
tute (NHLBI) Exome Sequencing Project (ESP, Seattle, WA)
database, which includes data of over 5,000 exomes, and
the exomes of 367 Finnish individuals sequenced at the
Wellcome Trust Sanger Institute (K. Rehnstro¨m and A. Pal-
otie, personal communication). By Sanger sequencing 90
Finnish population controls, we found one heterozygous
carrier of c.2831delC (p.Pro944Leufs*7) and one of
c.3019delC (p.Leu1007Cysfs*62). Therefore, some muta-
tionsmight occur, most likely as a result of a founder effect,
at a low frequency in the Finnish population, whereas
some might be private mutations. Even if the observed
frequencies in controls were much lower than thoserican Journal of Human Genetics 90, 540–549, March 9, 2012 543
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Figure 3. Twelve Pedigrees with CRMCC-Associated CTC1 Mutations
Symbols filled with black indicate individuals for whom clinical data were available for the diagnosis of CRMCC. The affection status of
individuals F6:II-1 and F9:II-1 (symbols filled with gray) is unknown; their intrauterine growth was severely retarded, they were born
prematurely at gestational weeks 36 and 31þ3, respectively, and they died soon after birth but were not investigated further. Individual
F6:II-2 had clinically definite CRMCC, but his detailed clinical data and DNAwere not available for this study. The identified mutations
at the protein level are shown below each genotyped individual. DNA samples were available for all individuals with CTC1 alleles indi-
cated, except for F4:II-2 and F7:II-3, from whom only clinical information was available and for whom the genotypes (in parentheses)
were inferred from parental genotypes. ‘‘wt’’ denotes no mutation.estimated for the diseases of the so-called Finnish disease
heritage,13 it is somewhat surprising that no individuals
homozygous for the two most frequently encountered
alterations (p.Val665Gly and p.Pro944fs*) were identified.
Whether such individuals exist and present with a typical
CRMCC or a different phenotype remains to be explored
by molecular analysis of further patients.
CTC1 is a component of the trimeric CST complex
composed of CTC1, OBFC1 (STN1, oligonucleotide/oligo-
saccharide-binding fold containing 1 [MIM 613128]),
and TEN1 (telomerase capping complex subunit homolog
[S. cerevisiae (MIM 613130)]).14 The CST complex binds to
single-stranded DNA (ssDNA) in a sequence-independent544 The American Journal of Human Genetics 90, 540–549, March 9manner and associates constantly with a fraction of telo-
meres, thus probably participating in the protection of
telomeres from lethal DNA degradation.14 CTC1 is pre-
dicted to contain three oligosaccharide-binding (OB)-fold
domains (Figure 2), suggested to be involved in ssDNA
binding.14 The two N-terminal OB-fold domains mainly
contribute to the DNA-binding activity of CTC1, whereas
the C-terminal 517 amino acids, which harbor the third
OB-fold domain, are responsible for the CST complex
formation through interaction with STN1 (Figure 2).14 In
F13:II-3 and F14:II-3, who had remained negative for
CTC1 mutations, we also sequenced the coding region of
the two other CTS-complex-encoding genes, STN1 and, 2012
Table 2. Summary of the Identified CTC1 Mutations
Nucleotide Change Exon
Amino
Acid Change
PolyPhen
Estimate
c.680C>T 5 p.Ala227Val possibly
damaging
c.724_727delAAAG 5 p.Lys242Leufs*41
c.1058delC 6 p.Ser353Leufs*14
c.1994T>Ga 12 p.Val665Gly probably
damaging
c.2831delCa 17 p.Pro944Leufs*7
c.2923A>G 17 p.Arg975Gly probably
damaging
c.2954_2956delGTT 18 p.Cys985del
c.3019delC 19 p.Leu1007Cysfs*62
c.3425_3426delTCinsATa 22 p.Leu1142His probably
damaging
c.3583C>Ta 23 p.Arg1195*
c.3586_3606delb 23 p.Leu1196_Arg1202delc
aMutations found in whole-exome sequencing.
bThe deleted nucleotide sequence is 5’-TTGTCCTGCCTTTCTATCCGA-3’.
cThe deleted amino acid sequence is Leu-Ser-Cys-Leu-Ser-Ile-Arg.TEN1 (primers listed in Table S4). No mutations were iden-
tified.
CTC1 is evolutionarily highly conserved and has ortho-
logs in various plant and animal species, notably in verte-
brates.15 Interestingly, no orthologs have been identified
in C. elegans or Drosophila. The orthologs in primates are
approximately 97% identical to the human protein,
whereas the dog, mouse, and zebrafish orthologs are
76%, 69%, and 32% identical, respectively. The cysteine
at position 985, deleted in a Portuguese CRMCC-affected
individual (F12:II-1 in Figure 3), as well as three of the
four amino acids that were affected by missense substitu-
tions and predicted to be possibly or probably damaging
by the PolyPhen16 analysis, are highly conserved in
mammals (Figure 4). The Arg975Gly variant shows less
conservation (Figure 4) but is predicted to be probably
damaging. The p.Ala227Val change affects the first OB-
fold domain and might interfere with DNA binding
(Figure 2), whereas the mechanism by which the
p.Val665Gly mutant results in impaired CTC1 is less
obvious because the mutation does not affect a known
functional domain. The last two missense mutations, as
well as the cysteine deletion and the 7 aa deletion, are
located in the C-terminal region critical for STN1 binding
(Figure 2) and are thus predicted to affect the CST-complex
formation. The frameshift and premature-stop-codon
mutations might result in nonfunctional truncated
proteins, protein instability, or mRNA degradation
through nonsense-mediated decay.17 If translated, they
would probably result in deficient CST-complex formation.
Compatible with autosomal-recessive inheritance, no
clinical findings typical of CRMCC were found in hetero-The Amezygous CTC1 carriers. This indicates that one normal
copy of CTC1 is sufficient enough for the normal function
of CTC1 and the CST complex. Interestingly, individuals
with CRMCC in 10 of the 12 mutation-positive families
(Figure 3) carried a missense substitution on one allele,
and the other allele harbored a frameshift or a prema-
ture-stop-codon mutation, which are both predicted to
lead to a truncated protein or significant reduction or
even total lack of the mutant protein. Similar to missense
mutations, the two in-frame deletions in individual
F12:II-1 are likely to be translated to protein products
with altered functional properties. Only one CRMCC-
affected person (F5:II-1) carried two missense mutations
(Figure 3). Because no individuals had two frameshift or
nonsense mutations, it appears likely that such a combina-
tion would either be lethal or result in a different pheno-
type. In light of the results of experiments in which partial
knockdown of CTC1 in mammalian cells disturbed the cell
cycle and caused genomic instability and activation of
a DNA-damage response,15 lethality would not be unex-
pected because such phenomena in a developing embryo
would hardly allow survival.
Regarding the differences in phenotype, we either iden-
tified or inferred compound heterozygous CTC1mutations
in 13 individuals with CRMCC out of the 15 who were
analyzed. CTC1 mutations were identified in all individ-
uals who had onset in childhood and shared a full CRMCC
phenotype, including retinal vascular abnormalities, cere-
bral calcifications, and leukoencephalopathy with or
without intracranial cysts (Table 1). On the contrary,
CTC1 mutations were identified in only one (F8:II-1) of
three individuals with late-onset CRMCC; these individ-
uals were all devoid of clinical retinal abnormalities. The
two individuals without CTC1 mutations nevertheless
had intracerebral calcifications and cysts but no systemic
findings. This suggests that CTC1 is not responsible for
the adolescent- or adult-onset LCC phenotype. We are
not able to conclude, however, that this would also hold
true for the childhood-onset LCC phenotype4 because
individuals with such a phenotype were not encountered
in our study. Interestingly, the CTC1 mutation-positive
individual (F8:II-1) with late disease onset had a mild
CRMCCphenotype, and although he did not have cerebral
cysts and retinal changes, he had suffered from intra-
uterine growth retardation and had skeletal abnormalities.
We thus suggest that systemic findings are important in
diagnosing CRMCC and in selecting individuals for
CTC1-mutation analysis. Individuals with isolated cerebral
findings are not as likely to harbor mutations in this gene.
The wide spectrum of clinical manifestations observed in
CRMCC is not surprising considering the predicted func-
tion and wide expression of CTC1 in human tissues as
determined from data available in expression databases
(NCBI Gene Expression Omnibus [GEO] and BioGBS).
Expression of CTC1 in endothelial cells is in line with
the hypothesis that microangiopathy might be a primary
underlying pathological abnormality in CRMCC.1rican Journal of Human Genetics 90, 540–549, March 9, 2012 545
Figure 4. Conservation of the CTC1 Amino Acid Sequence among Different Species
Amino acid sequence alignments around the single amino acids affected by five CRMCC mutations are shown for selected species. The
figure is modified from data displayed in Ensembl Comparative Genomics Gene Tree alignment for CTC1. The amino acids affected by
a missense mutation or a 1 aa deletion in the individuals with CRMCC are highlighted with black. Mutation descriptions are indicated
under the sequences. PolyPhen16 analysis predicted the p.Ala227Val mutation to be possibly damaging and predicted the three other
missense mutations to be probably damaging.Finally, there are several overlapping features between
CRMCC and disorders in which telomere biology is known
to be affected. These are most obvious in Revesz syndrome
(RS, [MIM 268130]), a severe and rare variant of dyskerato-
sis congenita (DC [MIM 127550, 224230, 305000, 613987,
613988, 613989, and 613990]). RS is caused by heterozy-
gous mutations in TINF2,18,19 which encodes TRF1-inter-
acting nuclear factor 2 (MIM 604319), a major component
of the telomere protecting shelterin complex.20 In addition
to classical DC manifestations (dysplastic nails, oral leuko-
plakia, abnormal skin pigmentation, and bone-marrow
failure), RS is characterized by intrauterine growth retarda-
tion, retinal telangiectasias, exudative retinopathy, and
intracranial calcifications;18,19 such symptoms are strik-
ingly similar to those produced by CRMCC. However,
retinal angiomas and cerebral cysts are not characteristic
of RS, and cerebellar hypoplasia, which is typical for RS,
is not a feature of CRMCC. It is interesting, given that RS
and CRMCC both result from mutations in a gene respon-
sible for telomere maintenance, that one individual with
RS was reported to have gastrointestinal bleeding, portal
hypertension, and hepatopulmonary syndrome,21 which
are prominent features in some of our CTC1-mutation-
positive individuals.
Unlike the RS phenotype, DC phenotypes have seldom
been shown to include intracranial calcifications.22
However, retinal findings are fairly frequent. In a survey
of 28 individuals with DC, 21% were found to have
retinal-pigment-epithelium changes, neovascularization,546 The American Journal of Human Genetics 90, 540–549, March 9vascular sheathing, exudative retinopathy, or retinal
detachment.23 Unlike RS, the other known subtypes of
DC are caused by mutations in genes that code for either
telomerase components (telomerase RNA component,
TERC [MIM 602322] and telomerase reverse transcriptase,
TERT [MIM 187270]), which are responsible for proper
telomere replication and maintenance of chromosome
ends,24 or telomerase-associated proteins (dyskeratosis
congenita 1, dyskerin, DKC1 [MIM 300126], ribonucleo-
protein homolog [yeast] NHP2 [MIM 606470], ribonucleo-
protein homolog [yeast] NOP10 [MIM 606471], and WD
repeat containing, antisense to TP53, WRAP53 [MIM
612661]).19,25 A mutation in one of the first five genes or
TINF2 is detected in 50%–60% of individuals with DC.19
Mutations in CTC1 might need to be excluded in the re-
maining individuals with DC because of an overlap in
some retinal and associated findings, such as dysplastic
nails, abnormal skin pigmentation, and bone-marrow
depression, between DC and CRMCC. Because of the
phenotypic overlap, we also searched our whole-exome
data for additional mutations in DC-associated genes, but
none were observed.
DC-affected individuals who have mutations in telome-
rase and shelterin-complex components have abnormally
short telomeres.19,26 Previous studies indicated that, in
general, the telomere length does not seem to directly
correlate with the severity of the DC phenotype,19,26 but
an association between the shortest telomeres and the
most severe variants of DC was recently observed.27, 2012
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Figure 5. Telomere Length in CRMCC-Affected, Heterozygous
Carrier, and Control Individuals
Relative telomere length was determined for seven CRMCC-
affected individuals (ages 1–16 years) and their 41 controls (ages
7–21years; age matched þ/ 5 years) as well as for nine heterozy-
gous-mutation carriers (unaffected parents, ages 30–47 years) and
their 29 controls (ages 30–52 years; age matched þ/ 5 years). For
telomere-length measurement, leukocyte DNA of selected individ-
uals, matched for the DNA-extraction method, was studied by a
quantitative PCR-based method,29 as described before,30,31 with
small modifications. PCR reactions were run with a Biorad
CFX384 PCR machine controlled by the CFX Manager 2.0 soft-
ware. All samples were analyzed in triplicate. Quality control was
performed as described previously.31 Data analysis was carried
out in Microsoft Office Excel 2007. Samples were removed from
the data analysis if their values deviated more than 3 standard
deviations from the mean (N ¼ 2). No significant differences
were observed between affected or carrier and control individuals
(Student’s t test). The error bars represent standard deviation.Impaired telomerase function resulting in telomere
shortening also plays a role in age-related bone loss in
telomerase-deficient mice,28 which show an osteoporotic
phenotype that involves kyphosis and deteriorated bone
architecture mainly in the metaphyseal areas. These
features resemble the skeletal characteristics of our cases.6
To investigate whether telomere length is affected in
CRMCC, we used a quantitative PCR (qPCR)-based
method,29 as described before,30,31 with modifications
that are described in Figure 5. Using leukocyte DNA, we
determined the length of telomeres from seven individuals
with CRMCC (F1:II-1, F2:II-1, F3:II-1, F5:II-1, F6:II-3, F8:
II-1, and F11:II-1), nine heterozygous carrier parents, and
70 control individuals. In contrast to the findings for
individuals with DC, we did not observe any difference
in telomere length between individuals with CRMCC
and age-matched controls. We also did not observe a differ-
ence between heterozygous carriers and age-matched
controls (Figure 5). However, as expected, telomere length
in the younger age groups was longer (Figure 5). These data
imply that telomere length is not drastically affected in
CRMCC, although this should be studied in larger datasets
or with other methods.
It is also possible that CTC1 mutations do not directly
affect telomere length, but rather affect the biology of telo-
meres through some other mechanism. This hypothesis is
supported by CTC1-null mutant experiments in Arabidop-
sis and knockdown experiments of CTC1 in human
cell lines.15,32 Both experiments showed dysregulated
telomeres with genomic instability. In Arabidopsis-null
mutants, a severe telomere deprotection phenotype
accompanied by a rapid onset of developmental defects
and sterility was observed.15 The knockdown of CTC1
expression in human cell lines has indicated both sporadic
telomere loss and telomeres with multiple hybridization
signals.15,32 To further study telomere integrity in individ-
uals with CRMCC, we applied a fluorescence in situ
hybridization (FISH)-based method with the use of
a Cy3-labeled telomere (5’-TTAGGG-3’)3 probe to evaluate
the presence of telomere aberrations in metaphase spreads
of cultured lymphocytes of two individuals with CRMCC
(F5:II-1 and F6:II-3) and two controls (Figure S2). Contrary
to CTC1-knockdown findings,15,32 we did not observe
a significant difference between CRMCC-affected and
healthy individuals regarding the presence of signal-free
ends or the presence of telomeres with multiple hybridiza-
tion signals (Figure S2). Although limited to the investiga-
tion of only two CRMCC-affected individuals, these
findings, in line with our qPCR experiments, do not imply
severely compromised telomere integrity and might
further insinuate more complex underlying biology.
Because the colocalization of the CST complex and telo-
meres is only a partial one and because CST binds to ssDNA
in a sequence-independent manner, it has been suggested
that the CST complex has a more general role in DNA
metabolism, rather than one limited to telomeric sites.14
Experiments in mammalian cells have implied that CTC1The Ameplays a role in the stimulation of DNA polymerase a-pri-
mase activity by STN1.33 Recently, studies on Xenopus lae-
vis oocytes showed that CST is involved in the priming of
DNA synthesis on the ssDNA template.34 Thus, the role of
these processes in the pathogenesis of CRMCC also needs
to be explored through further experiments.
In conclusion, we here provide data showing that
compound heterozygous CTC1 mutations underlie child-
hood-onset CRMCC with cerebral and retinal vascular
abnormalities and might account for some cases of late-
onset disease with a normal fundus appearance. Detection
of CTC1mutations will aid the diagnosis and classification
of CRMCC and any related molecularly undefined disor-
ders, including those classified as DC variants, which
pose challenges because of the wide spectrum of clinical
manifestations. Our data provide the initial step toward
understanding the molecular pathogenesis of CRMCC
and investigating whether disturbed telomere mainte-
nance or DNA metabolism more generally accounts for
the multitude of symptoms—some of which are develop-
mental—associated with the defective CTC1 function.Supplemental Data
Supplemental data include 2 figures and 4 tables and can be found
with this article online at http://www.cell.com/AJHG.rican Journal of Human Genetics 90, 540–549, March 9, 2012 547
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While we were revising our manuscript, a paper
describing CTC1 mutations in individuals with Coats
plus appeared: Anderson, B.H., Kasher, P.R., Mayer, J.,
Szynkiewicz, M., Jenkinson, E.M., Bhaskar, S.S., Urquhart,
J.E., Daly, S.B., Dickerson, J.E., O’Sullivan, J., Leibundgut,
E.O. et al. (2012). Mutations in CTC1, encoding conserved
telomeremaintenance component 1, cause Coats plus. Nat
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